Aptevo Therapeutics Inc (APVO)

Etorro trading 970x250
Aptevo Therapeutics Inc (APVO) Logo

About Aptevo Therapeutics Inc

Aptevo Therapeutics Inc., a clinical-stage biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed product includes IXINITY, a coagulation factor IX therapeutic indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations. Its lead clinical candidate is APVO436, a bispecific immunotherapeutic protein that is in Phase 1/1b clinical trial for acute myeloid leukemia and high-grade myelodysplastic syndrome. The company’s preclinical candidates include ALG.APV-527, a bispecific antibody to target 4-1BB x 5T4; APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40; and other pre-clinical development stage therapeutics focused on immuno-oncology. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington. Address: 2401 4th Avenue, Seattle, WA, United States, 98121

Aptevo Therapeutics Inc News and around…

Latest news about Aptevo Therapeutics Inc (APVO) common stock and company :

Aptevo Therapeutics Announces Publication of a Scientific Article in Peer-Reviewed Journal, Frontiers in Aging
28 Sep, 2021 FinancialContent
12 Health Care Stocks Moving In Tuesday's After-Market Session
24 Aug, 2021 FinancialContent

Gainers Regencell Bioscience (NASDAQ:RGC) stock rose 51.24% to $23.14 during Tuesday's after-market session. Regencell Bioscience's ...

Aptevo Therapeutics Announces APVO436 Monotherapy is Active in Patients Who Have Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome
17 Aug, 2021 FinancialContent
Aptevo Therapeutics Reports Second Quarter Financial Results with Business Highlights
12 Aug, 2021 FinancialContent
Friday Sector Leaders: Water Utilities, Biotechnology Stocks
16 Jul, 2021 FinancialContent

In trading on Friday, water utilities shares were relative leaders, up on the day by about 2%. Leading the group were shares of Middlesex Water, up about 4.2% and shares of Companhia de Saneamento Basico up about 3.7% on the day.

Aptevo Therapeutics' Chief Scientific Officer, Jane Gross, PhD, to Present at Upcoming Cambridge Health Institute PEGS Virtual Conference
16 Jul, 2021 FinancialContent
Aptevo Therapeutics' Scientists to Present At Virtual Cell Engager Summit
30 Jun, 2021 FinancialContent
Aptevo Therapeutics Announces Inclusion in the Russell Microcap(R) Index
29 Jun, 2021 FinancialContent
12 Health Care Stocks Moving In Tuesday's Intraday Session
22 Jun, 2021 FinancialContent

Gainers Anavex Life Sciences (NASDAQ:AVXL) stock increased by 17.07% to $25.92 during Tuesday's regular session. As ...

48 Biggest Movers From Yesterday
22 Jun, 2021 FinancialContent

Gainers Lydall, Inc. (NYSE: LDL) shares jumped 85.4% to close at $61.72 on Monday after the company agreed to be acquired by ...

Mid-Afternoon Market Update: Dow Jumps Over 500 Points; Lydall Shares Spike Higher
21 Jun, 2021 FinancialContent

Toward the end of trading Monday, the Dow traded up 1.71% to 33,857.87 while the NASDAQ rose 0.63% to 14,119.16. The S&P also rose, ...

12 Health Care Stocks Moving In Monday's Intraday Session
21 Jun, 2021 FinancialContent

Gainers Anavex Life Sciences (NASDAQ:AVXL) shares moved upwards by 17.07% to $25.92 during Monday's regular session. ...

31 Stocks Moving In Monday's Mid-Day Session
21 Jun, 2021 FinancialContent

Gainers Lydall, Inc. (NYSE: LDL) shares climbed 82.3% to $60.68 after the company agreed to be acquired by Unifrax for $61.10 per ...

Mid-Morning Market Update: Markets Open Higher; CNH Industrial To Buy Raven Industries
21 Jun, 2021 FinancialContent

Following the market opening Monday, the Dow traded up 1.27% to 33,712.27 while the NASDAQ rose 0.32% to 14,075.68. The S&P also ...

Aptevo Therapeutics Insights: Return On Capital Employed
18 Jun, 2021 FinancialContent

In Q1, Aptevo Therapeutics (NASDAQ:APVO) posted sales of $2.42 million. Earnings were up 1.01%, but Aptevo Therapeutics still reported ...

Looking Into Aptevo Therapeutics's Return On Capital Employed
04 Jun, 2021 FinancialContent

During Q1, Aptevo Therapeutics's (NASDAQ:APVO) reported sales totaled $2.42 million. Despite a 1.01% in earnings, the company posted a ...

Aptevo Therapeutics Announces Expansion Phase of Lead Anti-Leukemia Drug APVO436 in Adult Patients with Acute Myeloid Leukemia
27 May, 2021 FinancialContent
Aptevo Stock Gains on Encouraging Single-Agent Activity for APVO436 In Leukemia Patients
26 May, 2021 FinancialContent

Aptevo Therapeutics Inc(NASDAQ: APVO) hasannounced positive resultsfrom Phase 1 dose-escalation trial evaluating ...

Aptevo Therapeutics Reports Positive Phase 1 Clinical Data for Its Lead Leukemia Drug Candidate APVO436 in Adults With Relapsed Acute Myeloid Leukemia
26 May, 2021 FinancialContent
American Eagle Completes Magnetotelluric Survey at its Golden Trend Property in the Cortez, Nevada; Publishes Interview with CEO Anthony Moreau and VP of Exploration Mark Bradley
17 May, 2021 Yahoo! Finance

American Eagle Gold Corp. (TSXV: AE) ("American Eagle" or the "Company") is pleased to announce that its contractor Zonge Engineering has completed a new Controlled Source Audio Magnetotelluric ("CSAMT") geophysical resistivity survey on the Company's flagship Golden Trend property. Golden Trend is located adjacent to and on-trend of Barrick and Newmont's Goldrush and Cortez Hills project.

Aptevo Therapeutics Reports First Quarter 2021 Financial Results
11 May, 2021 FinancialContent
Aptevo Therapeutics to Present at the American Association for Cancer Research Virtual Annual Meeting
09 Apr, 2021 FinancialContent
Aptevo Therapeutics Reports 2020 Financial Results and Provides Business Update
31 Mar, 2021 FinancialContent
The Daily Biotech Pulse: Lilly COVID-19 Antibody Cocktail Approved for Emergency Use, Gamida, Genfit Jump On Data, 2 IPOs
10 Feb, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Aptevo Confirms Receipt of Nominations and Proposal Notice
10 Feb, 2021 FinancialContent
Aptevo Therapeutics is Now Oversold (APVO)
19 Jan, 2021 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

Aptevo Therapeutics Provides Update on Ongoing APVO436 Phase 1 Clinical Trial
11 Jan, 2021 FinancialContent
Aptevo Therapeutics Inc. (APVO) Upgraded to Buy: Here's Why
06 Jan, 2021 Yahoo! Finance

Aptevo Therapeutics Inc. (APVO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).

RSI Alert: Aptevo Therapeutics (APVO) Now Oversold
29 Dec, 2020 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

Kaskela Law LLC Announces Investigation of Aptevo Therapeutics Inc. (APVO) and Encourages Shareholders to Contact the Firm
19 Dec, 2020 Yahoo! Finance

PHILADELPHIA, PA / ACCESSWIRE / December 19, 2020 / Kaskela Law LLC announces that it is investigating Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc (APVO) is a NASDAQ Common Stock listed in , ,

970x250